Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world dupixent study monitors eczema patients for years

NCT ID NCT03428646

Knowledge-focused Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers will collect information on their medical history, skin symptoms, and quality of life over time to see how the medicine works in everyday practice. The goal is to better understand the long-term effects and safety of Dupixent outside of a controlled clinical trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

858 people

The number who actually took part.

Started

Apr 2018

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The target population comprises adult and adolescent patients (male or female, ≥12 years old), who are initiating treatment with DUPIXENT® for AD according to the country-specific prescribing information.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female, 12 years of age or older at the baseline visit. NOTE: Adolescent patients (at least 12 years old, but less than 18 years) are eligible in the US or Canada only after DUPIXENT receives the respective country's regulatory approval for use in this age group. * Initiating treatment with DUPIXENT® as standard-of-care for AD according to the country-specific prescribing information (Note: Participants will be screened when they received their initial prescription for DUPIXENT®). * Willing and able to comply with study-related activities. * Able to understand and complete study-related questionnaires. * Provide signed informed consent or parental/legal guardian consent plus patient assent, where applicable. Key Exclusion Criteria: * Patients who have a contraindication to the drug according to the country-specific prescribing information label. * Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments. * Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • Regeneron Investigational Site

    Birmingham, Alabama, 35205, United States

  • Regeneron Investigational Site

    Gilbert, Arizona, 85234, United States

  • Regeneron Investigational Site

    Fountain Valley, California, 92708, United States

  • Regeneron Investigational Site

    Laguna Hills, California, 92653, United States

  • Regeneron Investigational Site

    Loma Linda, California, 92354, United States

  • Regeneron Investigational Site

    Los Angeles, California, 90025, United States

  • Regeneron Investigational Site

    Los Angeles, California, 90067, United States

  • Regeneron Investigational Site

    Manhattan Beach, California, 90266-2911, United States

  • Regeneron Investigational Site

    Newport Beach, California, 92663, United States

  • Regeneron Investigational Site

    Oceanside, California, 92056, United States

  • Regeneron Investigational Site

    Redondo Beach, California, 90277, United States

  • Regeneron Investigational Site

    Riverside, California, 92506-0174, United States

  • Regeneron Investigational Site

    Roseville, California, 95661, United States

  • Regeneron Investigational Site

    San Diego, California, 92123, United States

  • Regeneron Investigational Site

    Santa Monica, California, 90404, United States

  • Regeneron Investigational Site

    Thousand Oaks, California, 91320, United States

  • Regeneron Investigational Site

    New Haven, Connecticut, 06519, United States

  • Regeneron Investigational Site

    Coral Gables, Florida, 33146, United States

  • Regeneron Investigational Site

    Margate, Florida, 33063, United States

  • Regeneron Investigational Site

    West Palm Beach, Florida, 33406, United States

  • Regeneron Investigational Site

    Atlanta, Georgia, 30342-1703, United States

  • Regeneron Investigational Site

    Macon, Georgia, 31217, United States

  • Regeneron Investigational Site

    Marietta, Georgia, 30060-1047, United States

  • Regeneron Investigational Site

    Marietta, Georgia, 30152, United States

  • Regeneron Investigational Site

    Sandy Springs, Georgia, 30328, United States

  • Regeneron Investigational Site

    Champaign, Illinois, 61820, United States

  • Regeneron Investigational Site

    Chicago, Illinois, 60654, United States

  • Regeneron Investigational Site

    La Grange Park, Illinois, 60526, United States

  • Regeneron Investigational Site

    Skokie, Illinois, 60077, United States

  • Regeneron Investigational Site

    Springfield, Illinois, 62604, United States

  • Regeneron Investigational Site

    Fort Wayne, Indiana, 46804, United States

  • Regeneron Investigational Site

    Plainfield, Indiana, 46168, United States

  • Regeneron Investigational Site

    Overland Park, Kansas, 66215, United States

  • Regeneron Investigational Site

    Corbin, Kentucky, 40701, United States

  • Regeneron Investigational Site

    Louisville, Kentucky, 40202, United States

  • Regeneron Investigational Site

    Rockville, Maryland, 20850, United States

  • Regeneron Investigational Site

    Towson, Maryland, 21204, United States

  • Regeneron Investigational Site

    Upper Marlboro, Maryland, 20772, United States

  • Regeneron Investigational Site

    White Marsh, Maryland, 21162, United States

  • Regeneron Investigational Site

    Quincy, Massachusetts, 02169, United States

  • Regeneron Investigational Site

    Ann Arbor, Michigan, 48103, United States

  • Regeneron Investigational Site

    Bay City, Michigan, 48706, United States

  • Regeneron Investigational Site

    Troy, Michigan, 48084, United States

  • Regeneron Investigational Site

    Warren, Michigan, 48088, United States

  • Regeneron Investigational Site

    Columbia, Missouri, 65212-0001, United States

  • Regeneron Investigational Site

    Kirksville, Missouri, 63501, United States

  • Regeneron Investigational Site

    St Louis, Missouri, 63110, United States

  • Regeneron Investigational Site

    Lincoln, Nebraska, 68505, United States

  • Regeneron Investigational Site

    Henderson, Nevada, 89052, United States

  • Regeneron Investigational Site

    Las Vegas, Nevada, 89144, United States

  • Regeneron Investigational Site

    Brick, New Jersey, 08724, United States

  • Regeneron Investigational Site

    East Windsor, New Jersey, 08520, United States

  • Regeneron Investigational Site

    Edison, New Jersey, 08820, United States

  • Regeneron Investigational Site

    Piscataway, New Jersey, 08854, United States

  • Regeneron Investigational Site

    Elmhurst, New York, 11373-4831, United States

  • Regeneron Investigational Site

    Forest Hills, New York, 11374, United States

  • Regeneron Investigational Site

    Garden City, New York, 11530, United States

  • Regeneron Investigational Site

    Kew Gardens, New York, 11374, United States

  • Regeneron Investigational Site

    Lake Success, New York, 11042, United States

  • Regeneron Investigational Site

    Manhasset, New York, 11030, United States

  • Regeneron Investigational Site

    Mineola, New York, 11501, United States

  • Regeneron Investigational Site

    Mount Vernon, New York, 10552, United States

  • Regeneron Investigational Site

    New York, New York, 10012-1354, United States

  • Regeneron Investigational Site

    New York, New York, 10016, United States

  • Regeneron Investigational Site

    New York, New York, 10029, United States

  • Regeneron Investigational Site

    New York, New York, 10075, United States

  • Regeneron Investigational Site

    The Bronx, New York, 10467-2401, United States

  • Regeneron Investigational Site

    Troy, New York, 12180, United States

  • Regeneron Investigational Site

    Concord, North Carolina, 28025, United States

  • Regeneron Investigational Site

    Akron, Ohio, 44333, United States

  • Regeneron Investigational Site

    Athens, Ohio, 45701, United States

  • Regeneron Investigational Site

    Bexley, Ohio, 43209, United States

  • Regeneron Investigational Site

    Marion, Ohio, 43302, United States

  • Regeneron Investigational Site

    Mason, Ohio, 45040, United States

  • Regeneron Investigational Site

    Tulsa, Oklahoma, 74136, United States

  • Regeneron Investigational Site

    Portland, Oregon, 97239, United States

  • Regeneron Investigational Site

    Blue Bell, Pennsylvania, 19422, United States

  • Regeneron Investigational Site

    Philadelphia, Pennsylvania, 19107, United States

  • Regeneron Investigational Site

    Philadelphia, Pennsylvania, 19140, United States

  • Regeneron Investigational Site

    Sellersville, Pennsylvania, 18960, United States

  • Regeneron Investigational Site

    Yardley, Pennsylvania, 19067, United States

  • Regeneron Investigational Site

    Charleston, South Carolina, 29425, United States

  • Regeneron Investigational Site

    North Charleston, South Carolina, 29420-4211, United States

  • Regeneron Investigational Site

    Bellaire, Texas, 77401, United States

  • Regeneron Investigational Site

    Dallas, Texas, 75231, United States

  • Regeneron Investigational Site

    Grapevine, Texas, 76051, United States

  • Regeneron Investigational Site

    San Antonio, Texas, 78205, United States

  • Regeneron Investigational Site

    Sugar Land, Texas, 77478, United States

  • Regeneron Investigational Site

    Sugar Land, Texas, 77479, United States

  • Regeneron Investigational Site

    Arlington, Virginia, 22204, United States

  • Regeneron Investigational Site

    Norfolk, Virginia, 23502, United States

  • Regeneron Investigational Site

    Bellevue, Washington, 98004, United States

  • Regeneron Investigational Site

    Milwaukee, Wisconsin, 53226, United States

  • Regeneron Investigational Site

    Hamilton, Ontario, L8L 8E7, Canada

  • Regeneron Investigational Site

    Markham, Ontario, L3P 1X2, Canada

  • Regeneron Investigational Site

    Ottawa, Ontario, K1G 6G6, Canada

  • Regeneron Investigational Site

    Peterborough, Ontario, K9J 5K2, Canada

  • Regeneron Investigational Site

    Toronto, Ontario, M5G 1E2, Canada

  • Regeneron Investigational Site

    Québec, G1V 4X7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.